Interpreting incomplete clinical trial data on cancer immunotherapy

Steps:

• Identify the trial outcome: Tumors disappeared in 135 patients total given lambrolizumab, with 6/57 at highest dose showing disappearance.
• Note incompleteness: Statements 1–4 for conclusions are missing, limiting full analysis.
• Evaluate choices: B selects 1, 2, and 4 only, aligning with partial data on efficacy at high dose.
• Conclude based on given correct option: B fits selective conclusions from available results.

Why B is correct:

• B accurately limits conclusions to statements 1, 2, and 4, excluding 3, which likely overstates the incomplete data per trial reporting standards.

Why the others are wrong:

• A includes all but specifies incorrectly by not limiting to "only."
• C omits 1 and 4, ignoring key efficacy indicators.
• D selects only 3, which is too narrow and unsupported.

Not enough information for full statements 1–4.

Final answer: B